NICE to recommend rituximab for leukaemia5th March 2010
The National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending the drug rituximab (MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia.
The draft guidance recommends rituximab, in combination with fludarabine and cyclophosphamide, for the treatment of what is the most common form of leukaemia in the UK, except when the condition has not previously responded to fludarabine or has relapsed within six months of treatment, or has previously been treated with rituximab.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.